NASDAQ: MNOV - MediciNova, Inc.

Rentabilität für sechs Monate: -28.57%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan MediciNova, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

weitere details
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2005-02-08
ISIN US58468P2065
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.medicinova.com
Цена ао 1.47
Preisänderung pro Tag: 0% (1.5)
Preisänderung pro Woche: -1.96% (1.53)
Preisänderung pro Monat: -9.64% (1.66)
Preisänderung über 3 Monate: -27.54% (2.07)
Preisänderung über sechs Monate: -28.57% (2.1)
Preisänderung pro Jahr: +3.45% (1.45)
Preisänderung über 3 Jahre: -44.03% (2.68)
Preisänderung über 5 Jahre: -67.32% (4.59)
Preisänderung seit Jahresbeginn: -28.57% (2.1)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 71.61 1
P/BV 1.15 9
P/E 0 0
EV/EBITDA -2.11 0
Gesamt: 4.63

Effizienz

Name Bedeutung Grad
ROA, % -12.93 0
ROE, % -13.74 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0219 10
Gesamt: 8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 24.6 4
Rentabilität Ebitda, % -29.43 0
Rentabilität EPS, % -41.73 0
Gesamt: 0.8
Weitere Details

Institutionen Volumen Aktie, %
Essex Woodlands Management Inc. 1105941 2.25
Blackrock Inc. 699642 1.43
Vanguard Group Inc 623333 1.27
Citigroup Inc. 447957 0.91
Geode Capital Management, LLC 435733 0.89
Renaissance Technologies, LLC 174100 0.35
Bank of America Corporation 167959 0.34
State Street Corporation 157198 0.32
Northern Trust Corporation 153556 0.31
Dimensional Fund Advisors LP 152530 0.31



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k 1950 (75 Jahre)
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k 1966 (59 Jahre)
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer N/A 1978 (47 Jahre)
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer N/A 1965 (60 Jahre)
Mr. John O'Neil CPA Controller

Adresse: United States, La Jolla. CA, 4275 Executive Square - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.medicinova.com